Verekitug for Nasal Polyps
(VIBRANT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the effects of a new treatment, verekitug (UPB-101), for individuals with chronic rhinosinusitis and nasal polyps. The goal is to determine if verekitug can reduce nasal polyp size and improve symptoms compared to a placebo. Participants will receive either the treatment or a placebo every 12 weeks for 24 weeks. The trial seeks individuals diagnosed with nasal polyps severe enough to consider surgery and who experience ongoing symptoms like a runny nose or reduced sense of smell. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must have stable treatment for nasal polyps for at least 30 days before starting the trial and continue using a nasal spray like mometasone furoate during the trial.
Is there any evidence suggesting that verekitug (UPB-101) is likely to be safe for humans?
Research has shown that verekitug (UPB-101) has been tested in people with chronic rhinosinusitis with nasal polyps. In a recent study, participants received the treatment every 12 weeks for a total of 24 weeks. They tolerated it well, and the treatment significantly reduced the size of the polyps. No major safety issues arose during this period, suggesting that verekitug is generally safe for humans, with no serious side effects noted in the study.12345
Why do researchers think this study treatment might be promising for nasal polyps?
Most treatments for nasal polyps involve corticosteroids or surgery, which aim to reduce inflammation and remove the polyps. However, verekitug (UPB-101) is unique because it introduces a new mechanism of action by targeting specific pathways involved in the growth of nasal polyps. Researchers are excited about this treatment because it is administered subcutaneously every 12 weeks, offering a potentially more convenient and less invasive alternative to existing therapies. Additionally, verekitug contains a novel active ingredient, which could provide a more targeted approach, potentially resulting in better outcomes for patients with nasal polyps.
What evidence suggests that verekitug might be an effective treatment for nasal polyps?
Research has shown that verekitug (UPB-101), which participants in this trial may receive, may help shrink nasal polyps in people with chronic rhinosinusitis with nasal polyps (CRSwNP). In a recent study, patients who received verekitug every 12 weeks experienced a noticeable reduction in the size and number of their polyps compared to those who did not take the drug. The results were statistically significant, indicating they were unlikely due to chance, and clinically meaningful, demonstrating real benefits for patients. This makes verekitug a strong option among treatments for this condition.12678
Who Is on the Research Team?
Kiran Patel, MD
Principal Investigator
Upstream Bio
Are You a Good Fit for This Trial?
This trial is for adults aged 18-75 with chronic rhinosinusitis and nasal polyps who need surgery, have ongoing symptoms like runny nose or loss of smell, and have had a past flare-up treated with steroids. They must not be able to use systemic corticosteroids, agree to the study's consent form, and have been on stable treatment for at least 30 days.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive verekitug (UPB-101) or placebo subcutaneously every 12 weeks for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Verekitug (UPB-101)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Upstream Bio Inc.
Lead Sponsor